Posted by Michael Wonder on 21 Oct 2024
Drug price negotiations for obstructive hypertrophic cardiomyopathy drug Camzyos stall, delaying reimbursement
21 October 2024 - Urgent attention is on the drug price negotiations for the obstructive hypertrophic cardiomyopathy (oHCM) treatment Camzyos (mavacamten), raising anxiety among patients.
The deadline has reportedly passed for negotiating the drug price of Camzyos with the National Health Insurance Service, according to sources.
